VC Leading $100m Dementia Discovery Fund Reveals New Model
This article was originally published in Scrip
Executive Summary
A very early stage fund run by a venture capital firm purely for the discovery of disease-modifying drugs for the treatment of dementia – the Dementia Discovery Fund (DDF) – has been launched. Six pharma companies, the UK government and the charity Alzheimer's Research UK have raised $100m in total in the first closing. It will be run by SV Life Sciences (SVLS), a leading international life sciences VC firm. SVLS's Kate Bingham tells Scrip why she believes the DDF could provide the breakthrough needed to develop new drugs to treat dementia.
You may also be interested in...
Finance Watch: Dementia Discovery Fund Exceeds Fundraising Goal By $150m
Private Company Edition: The Dementia Discovery Fund started in 2015 with plans to raise $200m to fund early-stage development of disease-modifying drugs, but recently closed its fundraising with $350m in commitments. Also, Kaleido's $101m Series C is among three recent $100m-plus rounds.
Finance Watch: OncoMed Cuts Costs To Conserve Capital While Public, Private Peers Raise Cash
OncoMed lays off half its employees after a series of recent clinical setbacks. Meanwhile, six public companies raise $1.64bn in $100m-plus follow-on and debt offerings, SV Health Investors closed a $400m venture capital fund and eight therapeutics firms grabbed $247.5m in VC cash.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.